Abstract

A multicenter phase 1 trial published in Nature Medicine reports preliminary evidence for the safety and efficacy of in vivo base editing gene therapy in patients with heterozygous familial hypercholesterolemia (HeFH). Six participants received escalating doses of YOLT-101, an investigational adenine base-editing therapy delivered via GalNAc-modified lipid nanoparticles targeting hepatic PCSK9 inactivation. No grade ≥3 adverse events occurred, with transient infusion-related reactions and liver enzyme elevations representing the most common adverse events. At the highest dose (0.6 mg kg⁻¹), sustained reductions of 74.4% in circulating PCSK9 and 52.3% in low-density lipoprotein cholesterol (LDL-C) were observed at 24 weeks follow-up. While these findings suggest potential for durable lipid modification through single-dose gene editing, the small sample size and early-phase design limit conclusions regarding clinical efficacy and long-term safety. Larger controlled trials with cardiovascular endpoints will be necessary to establish the therapeutic role of in vivo base editing for HeFH management.

Introduction

Heterozygous familial hypercholesterolemia affects approximately 1 in 250 individuals worldwide and represents one of the most prevalent monogenic disorders associated with premature atherosclerotic cardiovascular disease.¹ Patients with HeFH typically demonstrate lifelong elevation of serum LDL-C concentrations, with levels often exceeding 190 mg/dL despite standard lipid-lowering therapy. Current treatment paradigms rely on combination pharmacotherapy, including high-intensity statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, yet a substantial proportion of patients fail to achieve guideline-recommended LDL-C targets.²

PCSK9 has emerged as a validated therapeutic target for LDL-C reduction through its role in regulating hepatic LDL receptor degradation. Monoclonal antibody inhibitors of PCSK9, including evolocumab and alirocumab, have demonstrated significant cardiovascular benefit in large randomized controlled trials, though their adoption remains limited by cost considerations and requirement for ongoing administration.³ Small interfering RNA (siRNA) approaches targeting PCSK9, such as inclisiran, have extended dosing intervals to twice yearly while maintaining substantial LDL-C reduction.⁴

The application of gene editing technologies to achieve permanent PCSK9 inactivation represents a novel therapeutic approach that could potentially eliminate the need for chronic medication administration. Base editing, a recent advancement in CRISPR technology, enables precise single-nucleotide modifications without generating double-strand breaks, potentially reducing off-target effects compared to conventional gene editing approaches. The current study represents the first reported clinical application of in vivo adenine base editing for PCSK9 inactivation in patients with familial hypercholesterolemia.

Study Design and Methods

The investigators conducted a phase 1, dose-escalation clinical trial evaluating YOLT-101, an investigational gene therapy employing adenine base editing technology delivered via GalNAc-modified lipid nanoparticles. The study enrolled six adults with heterozygous familial hypercholesterolemia and uncontrolled LDL-C concentrations despite standard therapy. Participants included three men and three women who received escalating single intravenous doses of YOLT-101 at 0.2, 0.4, or 0.6 mg kg⁻¹ (two participants per dose cohort).

The GalNAc modification of the lipid nanoparticle delivery system was designed to facilitate hepatocyte-specific uptake through asialoglycoprotein receptor-mediated endocytosis, thereby concentrating the base editing machinery within the target tissue. The adenine base editor was engineered to introduce specific nucleotide changes within the PCSK9 gene coding sequence, resulting in premature stop codons and functional protein inactivation.

Primary endpoints included safety and tolerability assessments through systematic monitoring of adverse events, clinical laboratory parameters, and vital signs. Secondary endpoints comprised measurements of circulating PCSK9 protein concentrations and serum LDL-C levels at predetermined intervals through 24 weeks post-administration. The investigators also conducted comprehensive genomic analyses to evaluate potential off-target editing effects, though specific methodological details for these assessments were not fully described in the available interim report.

The study employed standard Common Terminology Criteria for Adverse Events (CTCAE) grading for safety assessments. Statistical analyses for efficacy endpoints appear to have been descriptive given the small sample size, though the investigators did not provide detailed information regarding statistical methodology or power calculations in the interim publication.

Results

No grade ≥3 adverse events were observed across any dose cohort during the reported follow-up period. The most frequently reported adverse events included transient infusion-related reactions and elevations in hepatic aminotransferase concentrations, both of which resolved spontaneously without specific intervention. The investigators characterized these liver enzyme elevations as self-limited, though precise values and duration were not specified in the available interim data.

YOLT-101 administration resulted in dose-dependent reductions in circulating PCSK9 concentrations across all dose cohorts. In the highest dose group (0.6 mg kg⁻¹, n=3), mean PCSK9 levels demonstrated a sustained 74.4% reduction from baseline at 24 weeks post-treatment. Corresponding LDL-C reductions in this cohort reached 52.3% at the same timepoint, representing substantial and durable lipid modification following single-dose administration.

The investigators reported that these reductions appeared durable throughout the 24-week observation period, suggesting successful genomic modification rather than transient pharmacological effect. However, specific trajectory data for PCSK9 and LDL-C changes over time were not provided in sufficient detail to characterize the kinetics of gene editing efficacy.

Genomic analyses indicated absence of detectable off-target editing effects, though the methodology and sensitivity thresholds for these assessments were not fully described. The investigators employed multiple complementary approaches including Digenome-seq, GUIDE-seq, CIRCLE-seq, hybrid capture sequencing, whole-genome sequencing, and RNA-seq analysis to evaluate genomic specificity.

Individual participant responses demonstrated consistency within the highest dose cohort, though the small sample size precludes meaningful assessment of factors that might predict treatment response variability. No participants discontinued treatment or withdrew from follow-up assessments during the reported observation period.

Discussion

These preliminary results represent notable progress in the clinical translation of gene editing technologies for inherited lipid disorders. The magnitude of LDL-C reduction observed in the highest dose cohort (52.3% at 24 weeks) compares favorably to established PCSK9 inhibitor therapies, while the apparent durability of effect could potentially eliminate the need for chronic medication administration in appropriately selected patients.

The safety profile demonstrated in this small cohort appears acceptable for early-phase gene therapy investigation. Transient liver enzyme elevations following intravenous administration of lipid nanoparticles are consistent with previous experience using similar delivery platforms and likely reflect hepatocellular uptake rather than clinically meaningful hepatotoxicity. However, the limited sample size and follow-up duration preclude definitive safety conclusions, particularly regarding potential long-term consequences of permanent genomic modification.

The genomic specificity assessments, while reassuring in their reported absence of detectable off-target effects, require careful interpretation given the inherent limitations of current detection methodologies. Base editing technologies generally demonstrate improved specificity profiles compared to conventional CRISPR-Cas9 approaches, though comprehensive long-term safety data remain unavailable for any in vivo gene editing application in humans.

Several important limitations constrain the interpretation of these findings. The small sample size (n=6 total, n=3 in the highest dose cohort) provides insufficient statistical power to establish efficacy or characterize the full safety profile. The 24-week follow-up period, while adequate to demonstrate durability compared to conventional pharmacotherapy, remains insufficient to assess long-term safety or sustained efficacy of genomic modification. The study population was limited to patients with HeFH, and generalizability to other patient populations requiring LDL-C reduction remains unknown.

The investigators did not report baseline LDL-C concentrations or concomitant lipid-lowering medications, limiting assessment of absolute treatment effects and potential for achieving guideline-recommended targets. Furthermore, the study design did not include placebo controls, though such controls would be ethically challenging in patients with severe hypercholesterolemia requiring active treatment.

From a methodological standpoint, the dose-escalation design provides appropriate safety data for phase 1 investigation, though optimal dosing remains to be established through larger studies. The investigators have not reported plans for expansion cohorts or phase 2 trial design, both of which will be necessary to advance clinical development.

Limitations

Beyond the constraints inherent to early-phase investigation, several additional limitations merit consideration. The study enrolled exclusively patients with HeFH, representing a genetically defined population that may respond differently to PCSK9 inactivation compared to patients with polygenic hypercholesterolemia. The absence of cardiovascular endpoint data limits assessment of clinical benefit, though such endpoints would require substantially larger studies with extended follow-up. Cost-effectiveness analyses will be essential given the likely substantial expense of personalized gene therapy approaches.

Clinical Implications

For practicing physicians managing patients with familial hypercholesterolemia, these findings suggest potential future availability of single-dose therapeutic options for achieving sustained LDL-C reduction. However, multiple clinical and regulatory milestones must be achieved before such approaches become available in clinical practice.

The current results support advancement to larger phase 2 trials, which should incorporate randomized, controlled designs with cardiovascular endpoint assessments. Such studies will be necessary to establish clinical efficacy and define the patient population most likely to benefit from gene editing approaches. Given the prevalence of familial hypercholesterolemia in Pacific Islander populations served by Hawaii’s healthcare system, including Native Hawaiian patients who demonstrate increased cardiovascular risk, future studies should ensure appropriate representation of diverse ethnic groups.

Healthcare systems will need to develop infrastructure for genetic screening, patient selection, and long-term monitoring of gene therapy recipients. The John A. Burns School of Medicine and affiliated institutions including Queen’s Medical Center may play important roles in future clinical development, particularly given existing expertise in cardiovascular genetics and lipid disorders management.

Regulatory considerations will likely require extensive long-term safety data before approval, potentially including lifetime monitoring of treated patients. The cost implications of gene therapy approaches will necessitate careful health economic evaluation, though single-dose treatments that eliminate need for chronic medication could potentially provide long-term cost savings despite high initial expense.

For patients currently managing familial hypercholesterolemia with existing therapies, these developments should not alter immediate treatment decisions. Established approaches including high-intensity statins, ezetimibe, and PCSK9 inhibitors remain standard of care and have proven cardiovascular benefit. However, patients with inadequate responses to conventional therapy may represent future candidates for gene editing approaches as clinical development progresses.

The potential for single-dose treatment achieving durable LDL-C reduction could significantly improve medication adherence challenges that frequently limit effectiveness of chronic pharmacotherapy in lipid management. This consideration may be particularly relevant for younger patients with familial hypercholesterolemia who face decades of required medication administration.

References

1. Hu P, Dharmayat KI, Stevens CAT, et al. Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease. Circulation. 2020;141(22):1742-1759. doi:10.1161/CIRCULATIONAHA.119.044795

2. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. doi:10.1161/CIR.0000000000000625

3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-1722. doi:10.1056/NEJMoa1615664

4. Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387

5. Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722. doi:10.1056/NEJMoa1706198